Middle East Renal Biomarkers Market (2025 - 2033)

Middle East Renal Biomarkers Market Summary

The Middle East renal biomarkers market size was estimated at USD 191.23 million in 2024 and is projected to reach USD 399.33 million by 2033, growing at a CAGR of 8.67% from 2025 to 2033. The burden of kidney disease is increasing steadily across the Middle East, driven by high rates of diabetes, hypertension, and obesity. Chronic kidney disease (CKD) and acute kidney injury (AKI) are emerging as major public health concerns, creating a growing need for earlier and more accurate detection methods beyond conventional testing. CKD often progresses silently until advanced stages, which makes biomarker-based diagnostics especially valuable for early intervention. In January 2025, Biomed Central highlighted a recent population-based study in the Kingdom of Saudi Arabia that reported an overall prevalence of chronic kidney disease (CKD) of 4.76% (95% CI: 4.72-4.80%) among adults tested between 2015 and 2022.

Reports from the International Society of Nephrology (ISN) Global Kidney Health Atlas in 2024, as well as other studies, highlight that the Middle East and North Africa (MENA) regions have a high prevalence of CKD risk factors, including diabetes, obesity, and hypertension. This high burden underscores the urgent need for more effective early diagnostic tools, including advanced renal biomarkers, to enhance patient outcomes. The International Society of Nephrology Global Kidney Health Atlas reports that in the Middle East region, the prevalence of CKD ranged from ~5.24% to ~10.57% among different countries. Further, for the end‐stage kidney disease (ESKD) treated with renal replacement therapy in the Gulf region: one study in the GCC found a mean prevalence of ESKD of 551 per million population (pmp), with country‐specific extremes such as Oman (~1000 pmp) and Qatar (~347 pmp).

In July 2025, Serum KIM-1 and Cystatin C levels were assessed as early biomarkers for kidney injury by a study that included participants from Middle East University (MEU) and Al-Yarmouk University. According to the snippet's source, another study examined the use of serum KIM-1 as an early diagnostic marker for diabetic nephropathy and found markedly elevated levels in diabetic groups. This study may have involved researchers or institutions from the Middle East. In addition to being a biomarker for acute kidney injury (AKI), studies have shown that KIM-1 serves as an entry point for several enveloped viruses, including the Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2. Given the origin of MERS-CoV, this emphasizes a particular regional relevance for KIM-1 research.

The Middle East renal biomarkers industry is gradually moving toward advanced laboratory automation and precision diagnostic systems. Hospitals and reference labs in Saudi Arabia and the United Arab Emirates are adopting automated analyzers and multiplex immunoassays that enhance detection accuracy and reduce turnaround times. The integration of advanced chemistry analyzers, AI-based data interpretation, and cloud-linked laboratory information systems is allowing clinicians to identify kidney damage at earlier stages. International diagnostic companies are also expanding their regional partnerships, providing access to innovative biomarker panels, such as NGAL, KIM-1, and cystatin C, which help detect subclinical kidney injury before it becomes irreversible.

Saudi Arabia and the UAE are leading the region in healthcare infrastructure. Both countries have invested heavily in modern hospitals, laboratories, and digital health systems that enable advanced diagnostic testing. Kuwait closely follows with well-equipped tertiary hospitals and a growing network of diagnostic services. Oman and Qatar are enhancing their diagnostic infrastructure, but access to high-end testing remains limited outside major cities.

Several chronic conditions are associated with chronic kidney disease (CKD) and acute kidney injury (AKI). The associated conditions are illustrated below:

The table below highlights the prevalence of diabetes in the age group of 20 to 79 years:

Table 1 Comparison of Prevalence of Diabetes in 2021, 2030, and 2045

Source: International Diabetes Federation 2021, Grand View Research

Diabetes rates are rising globally, and the MENA region is witnessing particularly concerning trends. According to data from the International Diabetes Federation (2021), the number of people living with diabetes in the region is projected to increase by 87%, growing from 73 million in 2021 to approximately 136 million by 2045.

Market Concentration & Characteristics

The Middle East renal biomarkers market is characterized by a steady pace of innovation, particularly in transitioning from conventional markers, especially in the shift away from traditional markers like albuminuria and serum creatinine, toward more sensitive and targeted instruments, such as proenkephalin (penKid), NGAL, KIM-1, and TIMP2/IGFBP7. Diagnostic laboratories in countries like Saudi Arabia and the UAE are introducing advanced biomarker panels that can detect renal injury earlier and with higher specificity. The entry of global diagnostic firms, along with increasing hospital awareness of the clinical value of biomarker testing, is contributing to a more innovation-driven landscape. However, innovation remains concentrated among a few multinational suppliers, while local companies are primarily engaged in distribution rather than product development.

Mergers and acquisitions in this space are driven by the need to consolidate technology portfolios and expand regional reach. For example, on January 28, 2025, Diaverum (now part of M42) announced plans to enter the United Arab Emirates market, with operations set to begin in Abu Dhabi and Al Ain. The expansion will bring haemodialysis, home dialysis, and holiday dialysis services, and emphasise preventive care and education in response to the growing burden of chronic kidney disease (CKD) in the UAE.

The Middle East renal biomarkers industry is significantly influenced by national regulatory frameworks, which determine both the speed of product approval and the level of clinical adoption. Saudi Arabia’s SFDA and the UAE’s Ministry of Health and Prevention (MOHAP) are actively streamlining approval pathways for diagnostic tests, signaling a supportive regulatory environment for innovation. However, Oman, Kuwait, and Qatar still follow more traditional and slower regulatory processes, which can delay product launches. Harmonization of medical device and diagnostic regulations across the Gulf Cooperation Council (GCC) is gradually improving, allowing companies to seek region-wide registrations and accelerate commercialization timelines.

Product portfolios in the Middle East renal biomarkers market are expanding from basic laboratory tests to comprehensive biomarker panels that assess kidney function, detect early damage, and monitor disease progression. Manufacturers are focusing on integrating these biomarkers into point-of-care devices, automated laboratory platforms, and multiplex immunoassay systems. The growing availability of both protein-based and genomic biomarker assays is improving diagnostic precision. Additionally, partnerships between international test developers and regional laboratory chains are helping to expand access to new assays in tertiary hospitals and specialized nephrology centers.

Regional expansion is being driven by rising healthcare investment and a shift toward preventive diagnostics across the GCC countries. Saudi Arabia and the UAE remain the largest and most advanced markets due to their strong infrastructure, higher test volumes, and government focus on chronic disease management. Kuwait is emerging as a key secondary hub, with ongoing investments in public hospital laboratories and the private diagnostic sector.

Biomarkers Insights

The functional biomarkers market accounted for the largest market share of 51.81% in 2024, due to their established clinical use in evaluating kidney filtration and overall function through parameters such as serum creatinine, cystatin C, and blood urea nitrogen. These tests remain routine across hospitals and diagnostic laboratories in the Middle East, as they are cost-effective and supported by existing clinical guidelines. In March 2024, Bio Preventive Medicine Co. (Taiwan) announced a strategic partnership with the Kuwaiti firm AMG Co. to jointly launch its renal biomarker assay, DNlite-IVD103, in the Middle East and North Africa region. This partnership highlights growing commercial interest and the entry of novel biomarker technologies into the Middle East market. The widespread use of functional markers reflects their reliability and the region’s focus on accessible diagnostic testing in both public and private healthcare settings.

The upregulated protein segment in the Middle East renal biomarkers industry is anticipated to grow at the fastest rate over the forecast period. This growth is driven by the increasing recognition of early kidney injury markers such as NGAL, KIM-1, TIMP2/IGFBP7, and proenkephalin, which allow detection before functional decline occurs. Hospitals and laboratories in Saudi Arabia and the UAE are increasingly integrating these advanced protein assays into diagnostic panels to improve early diagnosis and patient monitoring. The availability of automated testing systems and greater collaboration with global diagnostic manufacturers are further supporting the adoption of these novel biomarkers across the region.

Diagnostic Technique/Platform Insights

ELISA held the largest share of the Middle East renal biomarkers market in 2024. Enzyme-Linked Immunosorbent Assay (ELISA) remains one of the most widely used techniques for the detection and quantification of renal biomarkers due to its sensitivity, specificity, and ease of use, making it suitable for routine laboratory workflows in both public and private hospitals across the Gulf Cooperation Council (GCC) countries. The growing focus on early CKD screening has reinforced the role of ELISA-based kits, which are cost-efficient and compatible with automated laboratory systems.

The molecular diagnostics segment is anticipated to grow at a considerable CAGR over the forecast period. The region's steady transition to genomic and transcriptomic assays, which provide a more comprehensive understanding of kidney injury mechanisms and patient risk profiles, is contributing to the growth of this segment. International diagnostic firms are increasing the number of nucleic acid-based kits they offer, and research institutes in Saudi Arabia, the United Arab Emirates, and Qatar are investing in molecular testing capabilities. It is anticipated that molecular diagnostics will become more important in clinical and research settings for the management of renal disease as precision medicine initiatives gain traction in the Middle East.

End Use Insights

Hospitals and clinics dominated the Middle East renal biomarkers industry in 2024, accounting for a 54.33% share. They remain the primary end users of renal biomarker tests due to their robust diagnostic infrastructure, higher patient volumes, and integration of kidney function testing into standard clinical pathways. In Saudi Arabia and the UAE, hospitals are equipped with advanced diagnostic laboratories that routinely perform biomarker-based tests for patients with diabetes, hypertension, and other chronic conditions. The growing emphasis on early disease detection, combined with the availability of trained nephrology professionals, further reinforces this dominance.

The pharmaceutical & biotechnology companies segment is expected to grow at the fastest CAGR over the forecast period, fueled by rising investment in drug discovery and clinical research targeting kidney diseases. These companies are increasingly incorporating renal biomarkers into clinical trials for the assessment of efficacy and safety, particularly in the development of nephroprotective drugs. In addition, collaborations between biotech firms and academic hospitals in the Middle East are creating opportunities for biomarker validation studies and translational research, which will expand the use of biomarkers beyond diagnostics into therapeutic development.

Regional Insights

Saudi Arabia Renal Biomarkers Market Trends

Saudi Arabia is experiencing moderate to high growth in the Middle East renal biomarkers market. The Saudi government's initiatives to enhance healthcare infrastructure and increase awareness about kidney diseases are further driving market growth. Furthermore, in February 2024, as highlighted in an article, Saudi researchers are actively investigating the clinical efficacy of emerging biomarkers, such as plasma cystatin C and fibrinogen, as early indicators of diabetic nephropathy. These biomarkers are considered more reliable than traditional markers, like serum creatinine, in certain contexts. Studies conducted at institutions like the King Faisal Specialist Hospital and Research Center (KFSHRC) are using advanced techniques like metabolomics profiling to identify distinct metabolic signatures that differentiate between various stages of CKD and end-stage renal disease (ESRD).

UAE Renal Biomarkers Market Trends

The UAE renal biomarker market’s growth is driven by technological advancements, increasing approvals, and ongoing targeted screening programs using biomarkers. In February 2024, a study titled "Heritability of Kidney Biomarkers in the General Population" reported that kidney-related biomarkers have moderate to high heritability. For example, the heritability of estimated glomerular filtration rate (eGFR) was ~44%, urinary albumin excretion was ~20%, and the urinary albumin-creatinine ratio was ~18%. In April 2025, The Biomerica Inc. Fortel Kidney Disease Test received approval from the Ministry of Health and Prevention (UAE) for home use in the UAE. The rapid urine-albumin assay delivers results in around ten minutes and is aimed at individuals with diabetes and hypertension, two major risk groups in the UAE. This approval signals a strong shift toward consumer-centric diagnostics in the UAE and underscores the growing demand for early-detection renal biomarker tests. Further, as part of the UAE’s expanding diagnostic landscape, Genex Lab has established itself as a reliable player in clinical testing and preventive health screening. The laboratory provides a comprehensive range of diagnostic services, with a particular focus on renal health assessments. Among its offerings is the Blood Urea Nitrogen (BUN) test, which evaluates kidney function by measuring urea levels in the blood-a key indicator of how effectively the kidneys filter waste from the body.

Kuwait Renal Biomarkers Market Trends

Kuwait renal biomarker market’s growth is driven by the increasing prevalence of chronic kidney diseases (CKD) and acute kidney injury (AKI), which are often linked to a high incidence of diabetes and hypertension in the region. In June 2024, the Kuwait Center for Nephrology and Kidney Transplant officially opened its doors at the Al Sabah Hospital Complex in Shuwaikh, Kuwait. The new facility features 83 inpatient beds, 11 isolation rooms, 4 ICU beds, and 15 dialysis beds, and is dedicated to treating chronic kidney disease and performing kidney and stem cell transplants. This development reinforces the infrastructure for kidney disease care in Kuwait, signaling enhanced diagnostic and therapeutic capacity, which in turn can boost demand for advanced renal biomarker testing services and support market growth for renal diagnostics in the region.

Key Middle East Renal Biomarkers Company Insights

The Middle East renal biomarkers market’s growth is driven by a combination of established diagnostics companies and specialized innovators focused on expanding access and simplifying testing.

Recent Developments

• In April 2025, Biomerica secured regulatory approval from the UAE Ministry of Health and Prevention for its Fortel Kidney Disease urine microalbumin test, a ten-minute point-of-care assay for early detection of kidney damage. The approval highlights the UAE’s diagnostic readiness and priority on early intervention driven by high diabetes (>12 % of adults) and hypertension (estimated 29-35 %) prevalence. For the Middle East renal biomarkers market, this signals increasing market access and rising competition from global diagnostic firms entering the region.

• In March 2024, Bio Preventive Medicine Co. (Taiwan) announced a strategic partnership with Kuwaiti firm AMG Co. to jointly launch its renal biomarker assay DNlite-IVD103 in the Middle East and North Africa region. This partnership highlights growing commercial interest and the entry of novel biomarker technologies into the Middle East market

Middle East Renal Biomarkers Market